Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Abstract Introduction: Plasma biomarkers of Alzheimer’s Disease and Related Dementias (ADRD) pathology may help clarify how modifiable risk factors (MRFs) contribute to cognitive and functional impairment. Methods: Cross-sectional data from 1002 adults (mean age 72.0 ± 6.7) enrolled in the Bio-Hermes-001 study were analysed. First, block regression models assessed the added predictive value of MRFs and ADRD plasma biomarkers on cognitive (Mini-Mental State Examination, [MMSE]) and functional outcomes (Functional Activities Questionnaire, [FAQ]), beyond MRFs alone. Second, latent path analysis (LPA) examined ADRD neuropathology mediation pathways between MRFs and cognition and functional outcomes. Results: ADRD biomarkers significantly improved prediction models for MMSE (ΔR2 = 0.11) and FAQ scores (ΔR2= 0.11). Biomarkers of ADRD neuropathology mediated the impact of depression (B = -0.05), BMI (B = 0.02), and tobacco use (B = 0.14) on cognitive and functional outcomes. Discussion: ADRD biomarkers mediate key MRF effects on cognition and function, emphasising ADRD biomarker-driven preventive interventions targeting multiple MRFs. Longitudinal studies are needed to confirm causality.

Type

Journal article

Publisher

BMC

Publication Date

2026-06-02T00:00:00+00:00